Search results for " angiotensin II"

showing 6 items of 6 documents

Pericardium of the frog, Rana esculenta, is morphologically designed as a lymphatic space

2003

The importance of the pericardium and the pericardial fluid (PF) in the control of cardiac function has emerged over the past few years. Despite the acknowledgment that amphibians are exposed to both dehydration and excessive water accumulation, nothing is known about their pericardial structure and the morphological basis of the PF formation. We have studied the parietal pericardium (PP) morphology in Rana esculenta by electron microscopy. SEM images of the inner surface, which lines the pericardial cavity, revealed the presence of large vesicles and many small circular openings. TEM observations showed that the PP is made up of an inner mesothelial lining, often constituted by two layers …

AnimalAngiotensin IIRana esculentaAgricultural and Biological Sciences (miscellaneous)Lymphatic SystemMicroscopy ElectronAngiotensin II; Fluid transfer; Pericardial mesothelium; Rana esculenta; Angiotensin II; Animals; Endocrine Glands; Lymphatic System; Microscopy Electron; Pericardium; Rana esculenta; Agricultural and Biological Sciences (miscellaneous); Developmental Biology; AnatomyEndocrine GlandsAnimalsFluid transferPericardial mesotheliumAnatomyPericardiumEndocrine GlandDevelopmental Biology
researchProduct

Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide.

2020

Obesity has reached epidemic proportions in the United States and in much of the westernized world, contributing to considerable morbidity. Several of these obesity-related morbidities are associated with greater risk for death with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 penetrates human cells through direct binding with angiotensin-converting enzyme 2 receptors on the cell surface. Angiotensin-converting enzyme 2 expression in adipose tissue is higher than that in lung tissue, which means that adipose tissue may be vulnerable to COVID-19 infection. Obese patients also have worse outcomes with COVID-19 infection, including respiratory failure, n…

BMI body mass indexmedicine.medical_treatmentAdipose tissue030204 cardiovascular system & hematologyCHD coronary heart diseaseHF heart failureUS United States0302 clinical medicineRAAS renin-angiotensin-aldosterone systemPandemicMedicine030212 general & internal medicineCDC Centers for Disease Control and PreventionCOVID-19 coronavirus disease 2019TNF tumor necrosis factorHFpEF HF with preserved ejection fractionCV cardiovascularGeneral MedicinePrognosisICU intensive care unitPA physical activityMetS metabolic syndromePAH pulmonary arterial hypertensionCoronavirus Infectionsmedicine.medical_specialtyAF atrial fibrillationACE angiotensin-converting enzymePneumonia ViralCVD cardiovascular diseaseSARS-CoV-2 severe acute respiratory syndrome coronavirus 2ArticleSeverity03 medical and health sciencesBetacoronavirusInternal medicineIPF idiopathic pulmonary fibrosisHumansObesityMortalityHTN hypertension or hypertensivePandemicsMechanical ventilationAng II angiotensin IIbusiness.industrySARS-CoV-2CKD chronic kidney diseaseCOVID-19T2DM type 2 diabetes mellitusmedicine.diseaseAngiotensin IIObesityIL interleukinPneumoniaRespiratory failureMetabolic syndromebusinessSNS sympathetic nervousMayo Clinic proceedings
researchProduct

Transforming growth factor β1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive s…

2005

Objective To verify the benefit of renin–angiotensin system blockade in hypertension, the effects of 24 weeks’ losartan and ramipril treatment, both alone and in combination, on urinary albumin excretion (UAE) and circulating transforming growth factor b1 (TGFb1) have been evaluated in hypertensive subjects with minor renal abnormalities. Design and methods Fifty-one patients with stage 1 and 2 essential hypertension and with UAE >—20 mg/24 h but with maintained renal function have been included. After a 4-week run-in with placebo administration, a randomized double-blind, three-arm double-dummy trial was used. All the hypertensives (HT) were allocated randomly to three treatment arms (1…

MaleRamiprilmedicine.medical_specialtyAngiotensin receptorHypertension RenalPhysiologyAngiotensin-Converting Enzyme InhibitorsPharmacologyKidneySeverity of Illness IndexLosartanAce-inhibitors Angiotensin II receptor blockers hypertensive renal disease transforming growth factor β1.Transforming Growth Factor beta1transforming growth factor b1RamiprilTransforming Growth Factor betaInternal medicineInternal MedicinemedicineHumansRenal Insufficiencybusiness.industryMiddle AgedAngiotensin IIBlockadeangiotensin II receptor blockerEndocrinologyLosartanhypertensive renal diseaseRenal physiologyACE inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessangiotensin-converting enzyme-inhibitorAngiotensin II Type 1 Receptor BlockersBiomarkersTransforming growth factormedicine.drug
researchProduct

Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabet…

2016

Introduction: Combination therapy is needed to control blood pressure (BP) in a large number of hypertensive patients with diabetes mellitus. Adherence to treatment is a major clinical problem; therefore, the time duration of the antihypertensive action of a drug determines BP control when a dose is skipped. Objectives: The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine provides equal efficacy and safety as the perindopril/amlodipine combination when a drug dose is missed. Methods: In this noninferiority trial with a randomized, double-blind, double-dummy parallel group, controlled design, 260 patients received either olmesartan 20-40 mg/amlodipine 5-10 mg …

MaleSettore MED/09 - Medicina InternaAntihypertensive agentsPhysiologyMissed DoseTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood Pressure030204 cardiovascular system & hematologyPharmacologyEssential hypertensionlaw.invention0302 clinical medicineDiabetes mellitusRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerDrug CombinationPerindoprilMedicine030212 general & internal medicineAntihypertensive agentTetrazoleImidazolesSettore MED/37 - NeuroradiologiaMiddle AgedCalcium Channel BlockersDrug CombinationsTreatment OutcomeHypertensionFemaleEssential HypertensionOlmesartanCalcium Channel BlockerCardiology and Cardiovascular MedicineType 2circulatory and respiratory physiologymedicine.drugHumanAdultmedicine.medical_specialtyAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineDiabetes mellitumissed dose; hypertension; therapeutic efficacyCombination therapyUrologytherapeutic efficacyNOMedication Adherence03 medical and health sciencesDouble-Blind MethodInternal MedicineHumansOlmesartanAmlodipineamlodipine antihypertensive agents blood pressure diabetes mellitus olmesartan perindoprilImidazolemissed doseAgedbusiness.industryAngiotensin-Converting Enzyme Inhibitormedicine.diseaseAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Perindopril; Tetrazoles; Treatment Outcome; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineBlood pressureDiabetes Mellitus Type 2PerindoprilAmlodipinebusinessAngiotensin II Type 1 Receptor Blockers
researchProduct

Antihypertensive and cardiovascular effects of combined blockade of renin-angiotensin system with ACE inhibitor and angiotensin II type 1 receptor bl…

2006

BACKGROUND.: In this study the effects of 24 weeks losartan and ramipril treatment, both alone and in combination, on blood pressure and left ventricular mass (LVM) and function, have been evaluated in hypertensives. METHODS.: 57 hypertensives with stage 1 and 2 essential hypertension were included. After 4 weeks run in, a randomized double-blind, 3 arm, double dummy, independent trial was used. All patients were randomly allocated to 3 treatment arms consisting of losartan (50 mg/daily), ramipril (5 mg/daily), and combined (losartan 50 mg/ramipril 5 mg/daily) for 24 weeks. LVM, LVM/h(2.7) and other echocardiographic measurements, BUN, creatinine and clearance and potassium were determined …

Ramiprillcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyLeft ventricular geometry and functionAngiotensin II receptor blockersLeft ventricular hypertrophyEssential hypertensionArticlechemistry.chemical_compoundInternal medicinemedicineAce-inhibitors Angiotensin II receptor blockers Left ventricular geometry and functioncardiovascular diseasesAce-inhibitorsCreatininebusiness.industrymedicine.diseaseAngiotensin IILosartanBlood pressurechemistrylcsh:RC666-701ACE inhibitorCardiologyCardiology and Cardiovascular Medicinebusinessmedicine.drugHeart International
researchProduct

Antihypertensive and cardiovascular effects of combined blockade of renin-angiotensin system with ACE inhibitor and angiotensin II type 1 receptor bl…

2006

Background: In this study the effects of 24 weeks losartan and ramipril treatment, both alone and in combination, on blood pressure and left ventricular mass (LVM) and function,have been evaluated in hypertensives. Methods. 57 hypertensives with stage 1 and 2 essential hypertension were included. After 4 weeks run in, a randomized double-blind, 3 arm, double dummy, independent trial was used. All patients were randomly allocated to 3 treatment arms consisting of losartan (50 mg/daily), ramipril (5 mg/daily), and combined (losartan 50 mg/ramipril 5 mg/daily) for 24 weeks. LVM, LVM/h and other echocardiographic measurements, BUN, creatinine and clearance and potassium were determined after ru…

Settore MED/09 - Medicina InternaAce-inhibitors Angiotensin II receptor blockers Left ventricular geometry and functionSettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct